Sutro Biopharma Inc. (STRO) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sutro Biopharma Inc. (STRO:NASDAQ), powered by AI.

Current Price
$28.17
P/E Ratio
-1.3
Market Cap
239M
Sector
Healthcare
What is the Sutro Biopharma Inc. stock price forecast?

Sutro Biopharma Inc. is currently trading at $28.17. View real-time AI analysis on Alpha Lenz.

What is Sutro Biopharma Inc. insider trading activity?

View the latest insider trading data for Sutro Biopharma Inc. on Alpha Lenz.

What is Sutro Biopharma Inc.'s P/E ratio?

Sutro Biopharma Inc.'s P/E ratio is -1.3.

Sutro Biopharma Inc.

NASDAQ · STRO
$28.17-2.03(-6.72%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Sutro Biopharma Inc.'s future dividend policy...
Alpha Chat Insight

Sutro Biopharma Inc. trades at a P/E of -1.3 (undervalued) with strong ROE of 435.0%. 3Y revenue CAGR of 14.8% highlights clear growth momentum.

Ask for details

Company Overview

Sutro Biopharma Inc. is a clinical-stage biopharmaceutical company dedicated to the development and manufacture of novel oncology therapies. The primary focus of Sutro is on advancing its proprietary platform for designing and developing antibody-drug conjugates (ADCs), bispecific antibodies, and other protein-based therapeutics. These innovations are geared towards treating various cancers, aiming to improve the efficacy and safety profiles of cancer treatments. Sutro's unique approach leverages its cell-free protein synthesis technology, which allows for rapid and cost-effective production of complex biologics. This capability not only accelerates the drug development process but also enhances the scalability of manufacturing, supporting large-scale clinical trials and potential commercialization. The company plays a pivotal role in the biotechnology and healthcare sectors, contributing significantly to the pipeline of promising cancer therapeutics. Positioned within the vibrant landscape of biotechnology firms, Sutro Biopharma Inc. represents a notable player in the ongoing battle against cancer, driving cutting-edge research and development efforts for the biopharmaceutical market.

CEOMs. Jane Chung R.Ph.
SectorHealthcare
IndustryBiotechnology
Employees244

Company Statistics

FY 2025

Profile

$239.38MMarket Cap
$102.48MRevenue
0.00Shares Out
244Employees

Margins

N/AGross
-86.23%EBITDA
-102.41%Operating
-186.55%Pre-Tax
-186.45%Net

Valuation

-1.25P/E
-1.81P/B
2.34EV/Sales
-2.23EV/EBITDA
-1.34P/FCF

Growth (CAGR)

14.78%Rev 3Yr
19.12%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-68.12%ROA
435.02%ROE
-53.16%ROIC

Financial Health

$58.13MCash & Cash Equivalents
$248.15MNet Debt
-231.24%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Sutro Biopharma Inc. (ticker: STRO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 244 employees. Market cap is $239M.

The current price is $28.17 with a P/E ratio of -1.25x and P/B of -1.81x.

ROE is 435.02% and operating margin is -102.41%. Annual revenue is $102M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Sutro Biopharma Inc. (STRO) Stock Forecast 2026 $28.17 — Price, Financials & Analyst Targets | Alpha Lenz